Biodistribution and radiation dosimetry of the hypoxia marker 18F–HX4 in monkeys and humans determined by using whole-body PET/CT

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Nuclear medicine communications

• Publication date

  2010-10-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1097/MNM.0b013e3283407950PMID 20948452PMCID PMC3016990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PET imaging of hypoxia using [18F]HX4: a phase I trial

  2010cited by this paper
• Molecular imaging of hypoxia with radiolabelled agents

  2009cited by this paper
• PET imaging with hypoxia tracers: a must in radiation therapy

  2008cited by this paper
• TS‐1 enhances the effect of radiotherapy by suppressing radiation‐induced hypoxia‐inducible factor‐1 activation and inducing endothelial cell apoptosis

  2008cited by this paper
• Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.

  2008cited by this paper
• Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET

  2008cited by this paper
• Rakicidin A: a hypoxia-selective cytotoxin.

  2007cited by this paper
• Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

  2006cited by this paper
• Hypoxia imaging-directed radiation treatment planning

  2006cited by this paper
• OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

  2005cited by this paper
• Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides.

  2002cited by this paper
• A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes.

  2002cited by this paper
• 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies.

  2002cited by this paper
• Hyperthermia and hypoxia: new developments in anticancer chemotherapy.

  2001cited by this paper
• Click Chemistry: Diverse Chemical Function from a Few Good Reactions.

  2001cited by this paper
• SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies.

  1998cited by this paper
• Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies.

  1997cited by this paper
• Radiation dose to the bladder wall from 2-[18F]fluoro-2-deoxy-D-glucose in adult humans.

  1991cited by this paper
• Dose to the fetus from radionuclides in the bladder.

  1973cited by this paper

• Radiolabeled probes for tumor hypoxia imaging.

  2026cites this paper
• Hypoxia Inducible Factor-1α Specific Probe for Tumor Hypoxia Positron Emission Tomography Imaging.

  2025cites this paper
• PET Imaging of Metabolism, Perfusion, and Hypoxia

  2024cites this paper
• Non-FDG hypoxia tracers.

  2024cites this paper
• Molecular imaging of tumor hypoxia: Evolution of nitroimidazole radiopharmaceuticals and insights for future development.

  2023cites this paper
• Hypoxia A Typical Target in Human Lung Cancer Therapy.

  2023cites this paper
• Recent Advances of 68Ga-Labeled PET Radiotracers with Nitroimidazole in the Diagnosis of Hypoxia Tumors

  2023cites this paper
• Synthesis of a 2-nitroimidazole derivative N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([18 F]FBNA) as PET radiotracer for imaging tumor hypoxia

  2022cites this paper
• Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances

  2022cites this paper
• PET Oncological Radiopharmaceuticals: Current Status and Perspectives

  2022cites this paper
• Hypoxia and the phenomenon of immune exclusion

  2021cites this paper
• Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET

  2021cites this paper
• Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer

  2020cites this paper
• Approaches to PET Imaging of Glioblastoma

  2020cites this paper
• Biodistribution and radiation dosimetry of the novel hypoxia PET probe [18F]DiFA and comparison with [18F]FMISO

  2019cites this paper
• Comparative evaluation of [18F]DiFA and its analogs as novel hypoxia positron emission tomography and [18F]FMISO as the standard.

  2019cites this paper
• Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial

  2019cites this paper
• Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancers: a pilot study for integration into treatment planning

  2018cites this paper
• How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research

  2018cites this paper
• Biodistribution and Radiation Dosimetry of the Integrin Marker 64Cu-BaBaSar-RGD2 Determined from Whole-Body PET/CT in a Non-human Primate

  2017influential citation
• Radiopharmaceuticals in Tumor Hypoxia Imaging: A Review Focused on Medicinal Chemistry Aspects.

  2017cites this paper
• 18F-Fluoromisonidazole in tumor hypoxia imaging

  2017cites this paper
• Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer

  2016cites this paper
• Novel molecular imaging methods for cancer detection : more than meets the eye

  2016cites this paper
• Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer

  2016cites this paper
• Imagerie photoacoustique couplée à l’échographie haute résolution et à la fluorescence infrarouge en oncologie préclinique translationnelle

  2016cites this paper
• Imaging of tumor hypoxia with PET : a step towards individualized cancer treatment

  2016influential citation
• Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial

  2015cites this paper
• Automated radiosynthesis of GMP quality [18F]HX4 for PET imaging of hypoxia.

  2015cites this paper
• Development of PET probes for cancer imaging.

  2015cites this paper
• Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [18F]-tetrafluoroborate

  2015cites this paper
• The chemistry and radiochemistry of hypoxia-specific, radiohalogenated nitroaromatic imaging probes.

  2015cites this paper
• Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia – a simulation study

  2015cites this paper
• Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles.

  2015cites this paper
• Molecular imaging of hypoxia in non-small-cell lung cancer

  2015cites this paper
• Radiopharmaceuticals as probes to characterize tumour tissue

  2015cites this paper
• New ways to image and target tumour hypoxia and its molecular responses.

  2015cites this paper
• Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer.

  2015cites this paper
• Quantification and clinical applicability of novel oncology PET imaging biomarkers

  2015cites this paper
• Discovery and development of imaging-capable bacterial nitroreductases and their cytotoxic prodrugs for Clostridium sporogenes based gene therapy

  2015cites this paper
• A Comparative Study of the Hypoxia PET Tracers ( 18 F)HX4, ( 18 F)FAZA, and ( 18 F)FMISO in a

  2015cites this paper
• A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.

  2015cites this paper
• Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium

  2015cites this paper
• The hypoxic tumor microenvironment: from imaging to targeting

  2015cites this paper
• Personalized Medicine and Imaging In Vivo Quanti fi cation of Hypoxic and Metabolic Status of NSCLC Tumors Using [ 18 F ] HX 4 and [ 18 F ] FDG-PET / CT Imaging

  2014cites this paper
• Biodistribution and Radiation Dosimetry of the Carbonic Anhydrase IX Imaging Agent [18 F]VM4-037 Determined from PET/CT Scans in Healthy Volunteers

  2014cites this paper
• The Clinical Importance of Assessing Tumor Hypoxia: Relationship of Tumor Hypoxia to Prognosis and Therapeutic Opportunities

  2014cites this paper
• Radiolabelled probes targeting tumor hypoxia for personalized medicine.

  2014cites this paper
• Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 Affibody molecule

  2014cites this paper
• In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging

  2014cites this paper
• Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters.

  2013cites this paper
• Positron emission tomography radiotracers for imaging hypoxia.

  2013cites this paper
• A spatially resolved pharmacokinetic/pharmacodynamic model for bystander effects of the hypoxia-activated prodrug PR-104A

  2013cites this paper
• Development of bacterial nitroreductase enzymes for noninvasive imaging in cancer gene therapy

  2013influential citation
• Hypoxia imaging with PET: which tracers and why?

  2012cites this paper
• Imaging hypoxia to improve radiotherapy outcome

  2012cites this paper
• Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans

  2012cites this paper
• Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging

  2011cites this paper
• Current Molecular Imaging Positron Emitting Radiotracers in Oncology

  2011cites this paper
• Circulating Tumor Cells and PET

  2011cites this paper
• Traceurs de l’hypoxie en tomographie par émission de positons

  2011cites this paper